Pharmafile Logo

Market access and reimbursement in Canada – changes at CADTH

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? Join Clare Foy (Director – Global Market Access, Mtech Access) as she interviews Don Husereau (Adjunct Professor of Medicine, The University of Ottawa) on Friday 22nd March at 2.00pm (GMT)/10.00am (EDT)/3.00pm (CET) for our next Global Whispers webinar.

Market access and reimbursement in Canada – changes at CADTH

In this webinar, we will take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau will explore:

  • The market access landscape in Canada
  • Upcoming changes at CADTH
  • What Canadian payers expect from your value proposition
  • Opportunities and challenges when launching new medicines/medical devices/diagnostics in Canada
  • How Canada compares to the USA/key European launch markets
  • What this means for your global market access strategy

Learn more about this webinar

Register now

More about our speaker

Don Husereau (Adjunct Professor of Medicine, The University of Ottawa)

Don is an Adjunct Professor of Medicine at The University of Ottawa. He is a freelance healthcare researcher, and works with private and public sector life sciences organisations to help them understand the value of health technology and its implications for pricing, reimbursement, and healthcare and innovation policy. In Canada, he has served on National and Provincial Expert appraisal committees and has been an invited expert member of a Federal commission focused on innovation policy. He is also Co-Chair of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Task Force.

Don Husereau (Adjunct Professor of Medicine, The University of Ottawa)

We are delighted to welcome Don to the Global Whispers webinar series.

We invite you to put your questions to Don in this session. Please suggest a question when you register or email your questions to info@mtechaccess.co.ukRegister now to join us for the webinar.
If you cannot attend the webinar but would like to know more, please register nonetheless, as all registrants will receive a recording of the webinar.

The webinar is free and is open to all market access, HEOR, strategic and commercial teams in Pharmaceutical, Medtech and Diagnostics companies. We also welcome attendees from healthcare systems. Some colleagues from other organisations may attend at the discretion of Mtech Access.

This content was provided by Mtech Access

Company Details

 Latest Content from  Mtech Access 

The role of economic evaluation in US healthcare

Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking...

What role does ICER play in US market access?

The Institute for Clinical and Economic Review (ICER) is becoming an increasingly important player in US market access. As more transformative, but costly, treatments come to market, payers must continue...

Mtech Access are exhibiting at ISPOR in the US

After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...

Market access and reimbursement in Canada – changes at CADTH

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health...

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.

The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid

Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

Digital options to enhance your local market access materials

How can a digital approach enhance local customer communication, particularly when tools are adapted from existing global materials? What are the options? How can we build in efficiencies whilst meeting...

So, what is happening with specialised commissioning in the NHS?

Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional push back on the plans for...